FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C	20549	
wasinington,	D.C.	20343	

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Aunins John G.  (Last) (First) (Middle)  C/O SERES THERAPEUTICS, INC.  200 SIDNEY STREET						Issuer Name and Ticker or Trading Symbol Seres Therapeutics, Inc. [ MCRB ]      Date of Earliest Transaction (Month/Day/Year) 01/25/2019								lationship of Reporting Person(s) to Issuer ck all applicable)  Director 10% Owner  Officer (give title Other (specify below)  Chief Technology Officer				ner	
(Street)  CAMBRIDO  (City)	GE MA		2139 ip)		4. If Amendment, Date of Original Filed (Month/Day/Year)									ndividual or Joint/Group Filing (Check Applicable ) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	le I - Nor	n-Deriv	vative	Se	curities	Acqu	ıired,	Disp	osed of,	or Bene	ficially	Owned					
Date			Date	ansaction hth/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)				4. Securities Disposed O			4 and 5) Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		'. Nature of ndirect Beneficial Ownership		
								Code	v	Amount	(A) or (D)	Price					Instr. 4)		
COMMON STOCK 01/2				6/2019	5/2019		М		7,500	A	(1)	92,750			D				
		Т									sed of, o			wned					
Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemo Execution if any (Month/Da	Date,	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Da (Month/Day/Y		ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securitie Beneficia Owned Following Reported	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amount or Number of Shares		Transacti (Instr. 4)	ion(s)			
STOCK OPTION (RIGHT TO BUY)	\$6.01	01/25/2019			A		60,000		(2)	)	01/24/2029	Common Stock	60,000	\$0.00	60,00	00	D		
RESTRICTED STOCK UNITS	(1)	01/26/2019			M			7,500	(3)	)	(3)	Common Stock	7,500	\$0.00	12,50	00	D		

## **Explanation of Responses:**

- 1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- 2. The option will vest as to 25% of the shares on January 25, 2020. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
- 3. These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019, and 50% on January 26, 2020.

## Remarks:

/s/ Thomas J. DesRosier, attorney-in-fact for John G.

01/29/2019

Aunins

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.